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Diabetes, Endocrinology, and Obesity Branch, Immune Tolerance Section, National Institute of Diabetes and Digestive and
Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
Dendritic cells (DCs) are key antigen-presenting cells that have an important role in
autoimmune pathogenesis. DCs control both steady-state T cell tolerance and activation
of pathogenic responses. The balance between these two outcomes depends on
several factors, including genetic susceptibility, environmental signals that stimulate varied
innate responses, and which DC subset is presenting antigen. Although the specific
DC phenotype can diverge depending on the tissue location and context, there are
four main subsets identified in both mouse and human: conventional cDC1 and cDC2,
plasmacytoid DCs, and monocyte-derived DCs. In this review, we will discuss the role
of these subsets in autoimmune pathogenesis and regulation, as well as the genetic
and environmental signals that influence their function. Specific topics to be addressed
include impact of susceptibility loci on DC subsets, alterations in DC subset development,
the role of infection- and host-derived innate inflammatory signals, and the role of the
intestinal microbiota on DC phenotype. The effects of these various signals on disease
progression and the relative effects of DC subset composition andmaturation level of DCs
will be examined. These areas will be explored using examples from several autoimmune
diseases but will focus mainly on type 1 diabetes.
Keywords: dendritic cells, autoimmunity, type 1 diabetes, innate immunity, T cell tolerance, antigen presentation
Introduction
Dendritic cells (DCs) play a vital role in host immunity by inducing innate inflammatory responses
to pathogens, efficiently priming naïve T cells, activating memory T cells, and promoting B cell
activation. However, DCs are also integral in maintaining steady-state immune homeostasis by
continually presenting tissue-derived self-antigens to CD4+ and CD8+ T cells in the absence of
inflammatory signals, leading to tolerance against those self-antigens. DCs can affect induction of
both immunity and tolerance in several ways, including at the level of DC development, the relative
composition of DC subsets, and the extent of DC maturation.
Autoimmune diseases occur when autoreactive T and B cells escape negative selection in the
thymus and bone marrow, respectively, followed by breaks in peripheral tolerance mechanisms that
disrupt immune system homeostasis. Antigen-presenting cells (APCs), includingDCs, play a central
role both in the initial thymic selection of the T cell repertoire and in maintaining peripheral T cell
tolerance for autoreactive cells. DCs affect autoimmune diseases including T cell-centric diseases
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such as type 1 diabetes (T1D) and multiple sclerosis (MS) and
diseases thought to be mediated by B cells and antibodies, such
as systemic lupus erythematosus (SLE). For example, in non-
obese diabetic (NOD) mice, a model for T1D, DCs can modify
pathogenesis by appearing in pancreatic islets early in life and
presenting self-peptides to autoreactive T cells in the pancreatic
lymph node (1). Thus, altering DC number or phenotype can
affect disease progression (2).
Early interplay between innate immunity and target tissues is
often a hallmark of autoimmune disease (3, 4). The question of
DC effects on autoimmune disease centers on the possibility that
DCs could either induce or suppress autoreactive T cell responses
and focuses on DC proteins that would affect those interactions.
Initial studies of DC ablation showed that decreasedDCs-induced
autoimmunity because of an inability to maintain Tregs (5), yet
other studies have demonstrated that a loss of DCs actually
decreased disease severity by blocking activation of pathogenic
cells (6, 7). In both autoimmune patients and murine models of
autoimmunity, DCs exhibit alterations in phenotype or function
that could be due to underlying genetic defects or the chronic
inflammatory environment, and can affect both the initiation of
disease and later failure of tolerancemechanisms that lead to tissue
destruction such as loss of insulin-producing beta cells in T1D
(Figure 1). Understanding the balance between the regulatory and
pathogenic role of DCs is important for learning how to block
autoimmunity in the clinic.
The lack of uniform nomenclature and definitions of particular
DC populations can make comparison of data from different
groups difficult. Therefore, it is helpful to use the recent simpli-
fied nomenclature of cDC1, cDC2, pDC, and monocyte-derived
cells (Figure 2) that is based primarily on ontogeny with fur-
ther specialization depending on location, and highlights the
match between mouse and human DC subsets (16). Under this
system, steady-state DCs can be broken down into three main
subsets based on developmental origin, surface markers, and
function: plasmacytoid DCs (pDCs) that can produce high levels
of type 1 interferons (IFN), and two conventional DC (cDC)
subsets, cross-presenting cDC1 that expresses CD8 or CD103
in mice and cDC2 that express CD11b+ and efficiently stim-
ulate CD4+ T cell proliferation (Table 1). In humans, cDC1
expresses BDCA3 and cDC2 express BDCA1 (17, 18). pDCs
express BST2 and Siglec-H in mice and BDCA2 in humans
(19, 20). Further specialization of these DC subsets occurs in
peripheral tissues. Separate from these steady-state DC subsets,
monocytes that are activated to express MHC II share some
functional features with cDCs, such as expression of CD11b,
but their overall gene expression patterns are much closer to
monocytes than any DC subset (21, 22). Regardless, much of
the literature refers to these monocyte-derived cells as DCs.
Because GM-CSF can induce development of these monocyte-
derived DCs in vitro from both human and mouse monocytes,
this is a popular model, but it is important to recognize that
they are a separate entity from cDCs. This review describes
recent advances in our knowledge of the differential roles of
particular DC subsets and activated monocytes for tolerance
induction.
FIGURE 1 | The roles of DCs in autoimmune diabetes pathogenesis
at several disease stages. Three main phases of autoimmune
pathogenesis occur in type 1 diabetes (with parallel stages found in other
autoimmune diseases). Although defined by changes in T cell responses,
these stages are controlled by DCs and innate immunity. First, an innate
environmental trigger contributes to loss of peripheral tolerance and
priming of autoreactive T cells (8–11). These innate signals can be
infectious (A) or endogenous (B), and the result is to activate DC
populations that stimulate self-specific T cells (C,D). Next, in the chronic
phase of the disease, autoimmunity is tenuously balanced with regulation
(12, 13). DCs continue to respond to innate stimuli, but now some TLRL
block disease (E). DCs interact with effector T cells and regulatory T cells
to mediate both activating (F,G) and regulating interactions (H,I). Finally,
the balance tips to a failure of tolerance and tissue destruction mediated by
non-productive interactions between DCs and Tregs (J) and DCs giving
increased activating signals to Teff (K,L) (14, 15).
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FIGURE 2 | Dendritic cell subsets perform particular functions in
steady-state and inflammation. In steady-state tissues (left panel),
lymphoid-resident cDC1 and cDC2 bearing self-antigen can both suboptimally
stimulate naïve CD4+ and CD8+ T cells and cause deletional tolerance of
autoreactive cells. A subset of naïve CD4+ T cells that are stimulated by cDC1
will encounter TGF-β on the DC and induce Foxp3 and become a Treg. If a Treg
is stimulated by cDC2, it will clonally expand that population of Tregs. pDCs
have limited capacity to stimulate CD4+ T cells directly due to low MHCII and
costimulatory molecule levels. Under certain conditions, pDCs have been
demonstrated to produce IDO and induce Treg generation. During inflammation
(right panel), cDCs mature and can stimulate effector T cell responses, including
Th1 and Th17 cells often associated with autoimmune disease. cDC1 can
induce strong Th1 responses from naïve cells and cDC2 are more efficient in
expanding CD4 Teff. pDCs respond to inflammation by secreting large amounts
of type I interferons that can significantly alter the pathogenesis of autoimmune
diseases. Inflamed pDCs also upregulate MHCII, allowing efficient antigen
presentation. moDCs mature from circulating monocytes (Ly6+ in mice, CD14+
in humans) as they enter inflamed tissues. moDCs are adept at inducing Th1
responses via secretion of IL-12, but can also expand Tregs in some
circumstances.
The Role of Specific DC Subsets in
Autoimmunity
Conventional DCs: CD8+ cDC1 and CD11b+
DCIR2+ cDC2
The different roles of specific DC subsets in eliciting autoimmune
pathogenic responses versus tolerance induction are likely to be
important for successful immunotherapy. cDC1s and cDC2s are
primarily located in distinct anatomical locations in lymphoid
tissues and process and present antigen on MHCI and MHCII
differently, and thus cause different stimulation of CD8+ and
CD4+ T cells (29). Ultimately, cDC1s efficiently cross-present
antigens to CD8+ T cells, while cDC2s more efficiently stim-
ulate CD4+ T cells, although either DC subset can stimulate
both T cell subsets (26, 29). Using antigen-encoding chimeric
antibodies that bind lectins differentially expressed by DC sub-
sets to deliver antigen in vivo to specific DC subsets is one
valuable tool that has made it possible to compare the T cell
responses elicited in vivo by particular DC subsets. In mice,
anti-DEC-205 antibodies have been used to efficiently target anti-
gen to lymphoid-resident CD8+ DCs and migratory CD103+
cDC1s (34, 35). In non-autoimmune-prone mice, chimeric anti-
DEC-205 antibodies elicit tolerance induction in both CD4+ and
CD8+ T cells if no other inflammatory signals are added (i.e.,
steady-state tolerance), but can induce strong antigen-specific
immunity if given with toll-like receptor (TLR) ligands and
anti-CD40 (34, 36). Although less-studied, anti-DCIR2 has like-
wise been utilized to demonstrate that cDC2s are also tolero-
genic in vivo for both T and B cell responses under steady-state
conditions (29, 37).
In autoimmune-prone NOD mice, DEC-205+ cDC1s are able
to induce tolerance in autoreactive CD8+ T cells (27) but antigen
presented by these DCs stimulate Th1 responses in autoreac-
tive CD4+ T cells even without exogenous maturation signals.
This defect in steady-state tolerance is corrected by inhibition
of CD40/CD40L interactions (12). Indeed, NOD CD8+ cDC1s
express higher CD40 compared to C57Bl/6 CD8+ cDC1. By con-
trast, targeting antigen to DCIR2+CD11b+ cDC2s induce tolero-
genic responses even in this chronic autoimmune environment
and stimulation of T cells by DCIR2+ cDC2s can inhibit diabetes
development (38).
Other studies have also suggested a regulatory role of CD11b+
cells in NOD mice, but it is not clear exactly what APC subsets
are involved. Although tolerogenic CD11b+CD11c+ cells abro-
gate diabetes when directed to the pancreas via increased CCL2
(30), other work shows that CD11b+ DCs may be responsible
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TABLE 1 | Parameters of DC subsets relating to autoimmunity.
Dendritic cell
subsets
Plasmacytoid DCs cDC1 cDC2 Monocyte-derived DCs
Markers in mice SiglecH, CD11c  intermediate,
B220+BST2+
DEC205, XCR1, Clec9A, CD8,
or CD103
CD11b, DCIR2 (33D1) CD11b CD11c MHCII high,
DC-SIGN (CD209) DCIR2 negative
Markers in human CLEC4C (BDCA2), CD123,
CD11c low/neg
CD141 (BDCA3), XCR1,
Clec9A,
CD1c (BDCA1) CD14, MR (CD206)
Transcription factor E2-2, Spi-B Batf3, Irf8 IRF4, Notch2 Remains unclear
Precursor CDP CDP CDP cMoP
Main location Bone marrow and peripheral
lymphoid tissues
Lymph nodes and peripheral
tissues
Spleen and peripheral tissues Rare in steady state, inflammation
recruits precursors from BM to
lymphoid and peripheral tissues
Role in autoimmune
pathogenesis
Needed for early type I IFN that
elicits initiation of autoimmune
diabetes
Efficient activation of CD8+
T cells through
cross-presentation
Efficient proliferation of
pathogenic CD4+ T cells
May expand effector T cells
Role in tolerance
induction
Production of IDO, induction of
IL-10 and Trl
Uptake of apoptotic cells and
induction of new Tregs
Efficient proliferation of Tregs,
induction of Th2?
In vitro-derived GM-CSF BM DCs
expand Tregs and inhibit diabetes
Alteration in
autoimmunity
More type 1 IFN production. In
NOD, higher CD11c expression
Inability to induce CD4+ T cell
tolerance and Treg induction
May be pathogenic and
tolerogenic, but not clear due to
lack of separation with
monocyte-derived CD11b+ cells
In mice, more MHCIIhi monocytes
due to inflammation. In T1D
patients, monocytes make more
pro-inflammatory cytokines
Reference (4, 8, 9, 23–25) (12, 26–28) (29, 30) (31–33)
for aberrant stimulation of beta-cell specific CD4+ T cells in
NOD mice (23). Cells that are CD11b+CD11c+ include cDC2s
and monocyte-derived cells. Some of the monocyte-derived cells
express high levels of MHC class II, especially in inflammatory
settings (22). However, DCIR2 [and the corresponding antibody
clone 33D1 (39)] is clearly specific for cDC2 cells, and use of this
marker can separate monocyte-derived cells from cDC2s.
In addition to effects on the pathogenicT cells, cDCs can induce
and expand autoantigen-specific Tregs that can block or reverse
autoimmune pathology (40). Because DC interactions with Tregs
can be enhanced by expression of costimulators, such as CD86
(41, 42), activation or maturation of DCs can sometimes have
paradoxical effects on autoimmunity and the optimal DC state
for tolerance maintenance may be semi-mature. DC subsets have
different effects onTregs. cDC1DEC-205+DCs can induce FoxP3
perhaps via TGF-β expression, producing a regulatory compart-
ment of autoreactive T cells (28). cDC2 CD11b+ DCs do not
express TGF-β or efficiently induce Treg differentiation, but they
expand existing populations of Tregs and can thus contribute to
Treg-mediated suppression of autoimmunity (28, 43). However,
factors other than TGF-β likely have a role in Treg induction by
these DC subsets, as TGF-βmay only have aminor role in conver-
sion of Foxp3  Treg precursors into Tregs (44). A recent study has
shown the importance ofmigratoryDCs in driving Treg responses
(35). As these migratory DCs, which can express DEC-205, traffic
from distal tissue sites containing antigens potentially relevant for
autoimmune responses, defects in the ability of migratory DCs
to induce or expand Tregs may inhibit self-tolerance and increase
autoimmunity.
Like T1D, MS, and the associated mouse model, experimen-
tal autoimmune encephalomyelitis (EAE) are associated with
aberrant T cell activation. Although DCs are not necessary for
induction of EAE, several studies have demonstrated that DCs can
permit immune invasion into the central nervous system (CNS)
(45, 46). Both CD8+ and CD11b+ DCs are found in the CNS dur-
ing EAE, and can play a role in activating pathogenic T cells (47).
Ablation of DCs in EAEmodels do not alter disease incidence but
exhibit amelioration of disease severity, indicating that DCs play a
role in priming pathogenic T cells or generating the inflammatory
milieu (48). CD11b+ DCs are located at the blood–brain barrier,
and have been surmised to drive Th17 development that promotes
EAE. Indeed, DCs are probably amajor producer of inflammatory
cytokines in the CNS during EAE induction and the acquisition of
neuroantigens byDCs, as opposed to residentmicroglia, coincides
with EAE symptom onset (49, 50).
Experimental autoimmune encephalomyelitis, and other
induced autoimmune models, require immunization to break
self-tolerance and initiate disease pathogenesis, and are models
primarily for the effector phase of diseases such as MS and
rheumatoid arthritis (51). But, immunization with a strong
innate signal such as CFA may not be a good context to measure
the state of innate immune and antigen-presenting function in
a more chronic, but less dramatic, inflammatory environment
such as that found during natural autoimmune pathogenesis.
Therefore, in models such as EAE one can either intervene prior
to immunization, when the mouse has no inflammation, or after
immunization, when the inflammatory state may be distinct
from the chronic inflammation that is found in tissue-specific
autoimmune diseases. For example, several studies have shown
that targeting self-antigen to DEC-205+ DCs to mice prior to
inducing EAE can block disease, but the DCs are presenting
antigen in a non-inflammatory context (35, 52, 53). Targeting
antigen to DEC-205+ cDC1s in NOD mice after initiation of
autoimmunity induces an effector response, and cDC1s express
higher levels of CD40 in NOD mice even without addition of
TLRL or other innate stimulus (12). It is probable that other
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innate and regulatory pathways are deregulated in the context
of chronic autoimmunity; therefore, it is important that tests of
antigen-specific tolerance induction are performed in models
such as the NOD mouse that may better reflect the immune state
of autoimmune patients.
An unusual cDC population termed as merocytic DCs has
been identified that are CD11c+ MHCIIhi, but negative for both
CD8 and CD11b (54). Interestingly, this population can acquire
antigen from apoptotic fragments and is more numerous in NOD
mice, a trait that maps to the insulin-dependent diabetes (Idd)13
genetic susceptibility locus (55). Transfer of purified merocytic
DCs pulsedwith beta cell antigenwas shown to accelerate diabetes
in NOD mice (56). However, a specific positive marker has not
been identified for this population, making it difficult to ensure
it is a uniform population and to determine if these cells more
closely resemble cDC1 or cDC2.
Plasmacytoid Dendritic Cells
Plasmacytoid DCs are significant contributors of type 1 IFN after
stimulation via TLR7 or TLR9 and as such can facilitate autoim-
munity as is clearly the case with SLE (8, 57). However, they can
also play a significant role in regulation of immune responses by
secreting IDO, inducing Tregs or inhibiting pathogenic responses
(23, 24, 58, 59). Although evidence suggests that IFN-α from
pDCs in the pancreas of NOD mice early (2–4weeks of age) is
important for initiation of autoimmune diabetes, other groups
show that pDCs are only present in the islets later in the dis-
ease and play a protective role via IDO (4, 9, 23, 25). A recent
human study shows increased IFN-α from peripheral blood
pDCs in patients with type 1 diabetes (60). It is possible that
pDCs may be playing both a pathogenic and a regulatory role
in T1D, depending on disease stage and microenvironment, but
this needs further study. pDCs can also be relevant in some
contexts for antigen presentation. For example, depleting pDCs
exacerbates EAE and MHCII expression is needed on pDCs to
inhibit EAE (58, 59). Targeting of autoantigen to pDCs with
antibodies against SiglecH (a lectin expressed specifically on
pDCs) reduced CNS autoimmunity (61). Interestingly, although
targeting antigen to pDCs via SiglecH-induced T cell regulation,
antigen targeted to pDCs via BST2 resulted in immunity (62).
Two possible explanations for the divergent response are that
(1) siglecH has an ITIM motif, and when antibody binds, pDCs
produce less IFN and (2) although BST2 is specific to pDCs in
non-inflamed environments, many other APCs can upregulate
BST2 with inflammation (63).
Monocyte-Derived Cells
There are also several monocyte-derived cell populations that
appear to have therapeutic potential and the ability to drive T
cell tolerance via cell-intrinsic mechanisms or Treg induction.
As discussed above, some studies identifying roles for CD11b+
cells may actually be studying a monocyte-related population,
not cDCs. Bone marrow DCs generated in vitro with GM-
CSF are monocyte derived. GM-CSF BMDCs efficiently stimu-
late proliferation of self-specific Tregs that can effectively block
and reverse diabetes pathogenesis (31, 64). Both GM-CSF/IL-4-
derived DCs and IL-10-derived DCs are tolerogenic monocyte-
derived populations that can alter Treg populations and inhibit
autoreactivity (65, 66). These tolerogenic DCs are being actively
studied for possible therapies in human autoimmunity and for
blocking medical complications such as graft-versus-host disease
(67, 68). On the other hand, T1D patients have activated mono-
cytes in the peripheral blood that make elevated levels of pro-
inflammatory cytokines (32). Therefore, monocyte-derived DCs,
like other DC subsets, also can provide both tolerogenic and
immune activating signals that alter autoimmune pathogenesis
(Figure 1).
The Role of DC Development in
Autoimmunity
Induction and maintenance of T cell tolerance can be affected
by alterations in DC development, which occur via hematopo-
etic bone marrow precursors that become more specialized
toward the DC lineage, starting with committed myeloid pre-
cursors (c-kit+CX3CR1+Lin ), monocyte and DC precur-
sors (c-kit+CX3CR1  Lin ), and committed DC precursors
(c-kitloCX3CR1+CD115+Lin ) (69). pDCs are an indepen-
dent lineage that branch off from the cDCs at the CDP stage.
TNF-α/iNOS-producing DCs and Gr-1+ inflammatory DCs
differentiate from monocytes during inflammation via GM-CSF,
but are rare in steady-state mice (14, 70, 71).
Flt3L is known to be essential for the development of DCs.
pDCs and cDCs can be generated in vitro by culturing bone
marrow cells (that include DC precursors) with Flt3L. Exogenous
Flt3L boosts mouse and human DC numbers in vivo, including
both cDC1 and cDC2 (72, 73). Increased Flt3L expression results
in an increase in Tregs that correlates with the total number of
CD11c+ cells (5). Studies using different timing of Flt3L treatment
demonstrated thatDCs can either ameliorate type 1 diabetes when
given early in life or increase disease severity if Flt3L is given
at later time-points when pre-existing autoimmune T cells are
present (74). This underscores the dual nature of DC actions on
T cells in autoimmune disease.
Dendritic cells in NOD mice exhibit alteration from devel-
opment of DC subsets. cDC1 is underrepresented in NOD
mice (75). Indeed, studies using Flt3L treatment of NOD mice
increased CD8+ DC numbers and ameliorated disease, indicat-
ing that DCs are important for inhibiting diabetes progression
(76). However, more recent studies have determined that Batf3-
dependent DCs are necessary for induction of diabetes (77).
Batf3 is a transcription factor that regulates cDC1 differentia-
tion (78). These results highlight the dual roles that DCs play
in autoimmune responses (77). NOD mice also express lower
levels of IL-2 at steady-state than non-autoimmune-prone mice
(79). IL-2 is a diabetes-associated gene located within the Idd3
loci. Although research has focused on the role of IL-2 on T
cells and specifically Treg numbers in diabetes, IL-2 also affects
DC development. The lower levels of IL-2 present in NOD mice
lead to increased numbers of DCs and could play a role in
aberrant T cell activation. The increased spleen pDC numbers
observed in NOD but not Idd3/5 mice, inversely correlate with
respective IL-2 levels (80). Therefore, alterations in DC develop-
ment can alter pathogenesis of diabetes and other autoimmune
diseases.
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Genetic Susceptibility Genes can Alter
Autoimmune Pathogenesis via Effects on
Antigen Presentation and Innate Immunity
The genetic region with the highest risk association in most
autoimmune diseases is MHCII (81), which links autoimmunity
to antigen presentation. Exactly how particular alleles of MHCII
confer susceptibility or resistance is still not clear after decades of
extensive study, but the most widely held theory is that particular
alleles direct repertoire selection in the thymus, andmay affect the
specificity of peripheral tolerance as well. Other genes associated
with APCs have also been linked to various autoimmune diseases.
For example, as stated previously in the section on pDCs, genes
related to type 1 IFN are implicated in a number of autoimmune
diseases (82). In models of diseases such as SLE, several studies
have indicated that a loss of negative regulators of inflammation
(such as A20, Shp1, and Blimp1) specifically in DCs lead to
autoimmune phenotypes (83–86).
Some susceptibility genes, such as IL-2, protein-tyrosine phos-
phatase, non-receptor type 22 (PTPN22), and B lymphocyte-
induced maturation protein 1 (BLIMP1), studied primarily for
functional roles in lymphocytes also affect DC phenotype (83–
87). BLIMP1 is a transcriptional repressor that modulates the
MHCII loci, but can be ubiquitinated by the ubiquitin ligase
Hrd1 to increase MHCII expression in DCs, and loss of Hrd1
protected against EAE (88). PTPN22 is a tyrosine phosphatase that
is directly involved inTLR-mediated signaling and can profoundly
affect type 1 IFN production in innate immune cells (89). In
type 1 diabetes, many of the identified susceptibility loci affect
APCs. Genes in the Idd4 locus can alter both IL-12 and IFN
responses that affect antigen presentation and the type of T cell
responses that ensue (90). Bone marrow chimera studies have
shown that Idd3/5 and Idd9 can affect diabetes pathogenesis in T
cell-independent, DC-dependentmanner, although the particular
DC subsets involved have not been elucidated (91, 92). Idd3
encodes IL-21 in addition to IL-2, and polymorphic variants of IL-
21 and its receptor have been implicated in genetic susceptibility to
T1D (93). IL-21R-deficientDCs fail to acquire expression ofCCR7
to shuttle between the pancreas and draining lymph nodes or effi-
ciently express MHCII to induce autoreactive T cell pathogenesis
(94). Data utilizing NODmice congenic for the diabetes-resistant
alleles at the Idd3 and Idd5 loci demonstrated that expression of
these alleles is important in DCs for CD4+ T and CD8+ T cell
tolerance. Therefore, the disease-altering effects of these two loci
come from both lymphoid and non-lymphoid cells, and this may
be a common feature of genetic risk.
The Level of DC Maturation and Response
to Environmental Stimuli can Alter
Autoimmune Pathogenesis
Dendritic cells respond to numerous maturation signals during
host responses. An array of innate receptors, including TLRs
NOD-like receptors, RIG-I-like receptors, and AIM2-like recep-
tors, as well as receptors for inflammatory cytokines, are expressed
by DCs and act as environmental sensors. These receptors bind
ligands from the local microenvironment and induce maturation
of DCs, acting as a switch to induce effective adaptive immune
responses. In addition to pathogen-associatedmolecular patterns,
these innate receptors can bind endogenous ligands or danger-
associated molecular patterns, which can alter DC phenotype and
function. Host-generated chronic inflammation during autoim-
mune pathogenesis is one source of this non-pathogen-associated
innate immune signal (3). Because of these activating signals, DCs
in autoimmune individuals have an altered ability to induce toler-
ance [reviewed in Ref. (95)]. DCs play a major role in the home-
ostasis of regulatory T cells (Tregs) and can thus also indirectly
influence effector T cell activation and tolerance via these cells.
These interactions change at different stages of disease (Figure 1).
Therefore, DCs can contribute both to the pathogenesis and
regulation of autoimmunity.
The cytokine milieu in an autoimmune-prone individual or
animal can have important effects on DC phenotypes. Alterations
in DCs in NOD mice have been linked to diabetes progression,
and a type 1 interferon signature has been noted prior to T
cell activation within the pancreas (96, 97). GM-CSF BMDCs
from NOD mice express increased NF-κB and higher levels
of the Th1-inducing cytokine IL-12 and adenosine deaminase,
although it is not yet clear if cDCs display similar responses (33,
98, 99). Migratory DC populations express lower levels of the
immunomodulatory cytokine IL-10 in NOD mice as compared
to non-autoimmune-prone strains (13). TNF-α, which can be
produced in response to environmental stimuli that signal via
pattern recognition receptors, may be one major modulator of
DC function in autoimmune disease.Mice treated neonatally with
TNF-α exhibited more rapid diabetes progression that correlated
with increased expression of costimulatory proteins on CD11b+
DC subsets, while decreasing the number of CD8+ DC in the
pancreatic lymph nodes (100).
Pro-inflammatory DC function has been observed in MS, and
interferon-β is used to treat the disease. Although the precise
mechanism is not clear, IFN-β may act on DCs by inhibiting
trafficking or reducing T cell activation, possibly via DC apoptosis
(101, 102). By contrast, type 1 interferons have been prominently
implicated in SLE pathogenesis, linking the disease to pDCs.
Immune cells from SLE patients display a type 1 IFN signature,
and their pDCs have a greater capacity for stimulating pathogenic
T cells than pDCs from control patients (103). In new-onset T1D
patients, an IL-1 signature has been measured, yet mouse models
of T1D indicate an early role for type 1 IFN and T1D patients may
have increases in IFN-α-producing pDCs (60, 104). Therefore,
the nature of the inciting innate responses is not the same for
all autoimmune diseases, and more work needs to be done to
define the innate landscape in both human autoimmunity and the
corresponding mouse models.
In addition to cytokines, surface costimulatory markers are
altered in DCs from NODmice. Our work has demonstrated that
CD8+ DCs from NOD mice express increased levels of CD40
and that this increase alters their stimulatory capacity for self-
specific CD4+ T cells (12). In the context of autoimmune gastritis,
migratory DCs from the stomach also express a semi-activated
phenotype with small increases in CD40, CD86, and MHCII.
However, unlike the shift to effector T cell responses inNODmice,
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these semi-activated DCs are refractory to TLR stimulation and
maintain their ability to induce tolerant CD4+ T cells even in the
presence of DC maturation factors (105). NODmice that lack the
interaction between CD28 on T cells and CD80/CD86 on APCs
display accelerated disease and lack Tregs, showing that these pos-
itive costimulators associated with inflammation are also needed
tomaintain tolerance (15). DC responses to chronic inflammation
may be regulated by a number of mechanisms. Therefore, changes
in DC phenotype directly affect pathogenic and tolerogenic T cell
responses in autoimmunity.
Another source of innate signals is the microbiome, and alter-
ations in the composition of gut flora have been linked to human
autoimmune disease (106, 107). For example, in T1D, studies of
microbial composition in at risk individuals found that serocon-
verted subjects had lower diversity prior to disease onset (108),
and lower levels of bacteria that produce the regulatorymetabolite
butyrate compared to controls that did not develop autoantibod-
ies (109). In mouse models, where it is possible to go beyond
correlation and dissect mechanism, manipulations of microbial
content can alter autoimmune pathogenesis. In a model of arthri-
tis, the presence of segmented filamentous bacteria in the gut
induces systemic immune alterations, increased Th17 responses,
and was necessary for full arthritis development; these bacteria
alter diabetes pathogenesis in NODmice as well (110, 111). Com-
mensal flora is important triggers in a relapsing–remitting EAE
model, advancing both pathogenic T and B cell responses (112).
In NOD mice, the effects of microbiota on disease progression
are complex. Mice lacking Myd88 (that cannot respond to most
TLR signals) do not get diabetes, but NOD.Myd88 /  mice in
germ-free conditions do develop diabetes that can be blocked
by transfer of defined microbial communities (10). Gender and
hormonal differences also alter gut microbial composition and
alter diabetes risk (113, 114). Indeed, the mechanisms by which
microbial communities influence specific DC populations are just
beginning to be defined (115), but these changes could in turn
affect autoimmune pathogenesis.
Paradoxically, innate immune stimulators such as TLR ago-
nists can sometimes inhibit autoimmunity. In NOD mice, weekly
injections of many different TLR ligands, including poly(I:C)
(TLR3 agonist), LPS (TLR4 agonist), or P40 protein from Kleb-
siella (TLR2 agonist), can block diabetes development if started at
weaning (116). Poly(I:C) can block disease if treatment is started
as late as 10weeks of age, soon before the mice begin to develop
diabetes. The effect of eliminating TLR signaling varies depending
on the receptor. TLR9 expression is needed for development of
diabetes and EAE in mouse models (117, 118). Conversely, TLR4
deficiency accelerates diabetes development in NOD mice (119).
Therefore, the contribution of TLR signals to autoimmunity is
complex, and can either inhibit or exacerbate disease.
Effects of DC Maturation Thresholds on
Development of Autoimmunity
The balance between tolerance and chronic inflammation asso-
ciated with autoimmune disease can shift with relatively minor
changes in DC phenotype. And although DCs can be sufficient
for inducing autoimmune disease in several models, often other
APC populations will drive disease in the absence of DCs. Cos-
timulatory proteins on T cells and DCs act on multiple levels to
affect autoimmune phenotypes, often altering the effector T cell
to regulatory T cell ratio. Because some of the same costimulatory
signals are needed for stimulation of effector T cells and Treg, a
small change in level can alter the balance between these two cell
types. CD28 and CD40 have disparate effects on inducing these
T cell fates in NOD mice, as a loss of CD28 can restore diabetes
in CD40L-deficient mice and alters the number of Tregs in those
mice (120).
Changes in DC phenotype due to an inflamed system may
be at a lower level than those observed due to treatment with
exogenous stimulants or during acute infection. However, these
changes can have dramatic effects on disease progression. For
example, the less than twofold increase in CD40 on CD8+ DCs in
NOD mice likely helps cause a switch from tolerance to effector
responses in autoreactive T cells (12). CD40 expression levels
affecting T cell fate is also observed in T cell responses to CD40
heterozygous mice. In a Leishmania infection model, CD40+/ 
DCs-induced regulatory T cells while CD40+/+ DCs-induced
effector T cells, while exacerbating or dampening disease, respec-
tively (121). Indeed, these effects can be observed during both
Treg and Teff stimulation. Lower levels of CD40 on DCs were
associatedwith higher numbers of Tregs and inhibition of diabetes
in an infection-driven model of type 1 diabetes (122). Expression
of higher CD40 levels on APCs induced a greater proportion of
effector T cells (123).
These subtle differences in DC phenotype leading to large
differences in T cell outcomes present the possibility of a threshold
effect. As shown with the Leishmaniamodel, altering CD40 levels
without completely losing those signals or overexpressing the
protein can cause a profound change in T cell responses and alter
the systemic immune response. DCs play an important role in
the maintenance of immune homeostasis, and disrupting their
phenotype by a small amount could lead to severe downstream
alterations in effector responses. Thus, whether by genetic means
or by inflammation from secondary sources, altered DC cos-
timulation may push T cell and subsequent B cell responses to
be aberrantly reactive to self-proteins, starting off autoimmune
pathogenesis.
Alterations in DCs due to Chronic
Inflammation: Comparison to Infection
The inflammation that occurs during autoimmune pathogenesis
may have parallels with the T cell responses during chronic infec-
tion because long-lasting effector T cell responses can alter the
inflammatory state of a host, both via pro- and anti-inflammatory
mechanisms. The generation of antimicrobial T cells can pro-
duce responses that have inflammatory effects on host tissues, as
well as regulatory mechanisms to minimize host tissue damage
(124). Autoimmune diseases that have environmental etiologies
may have infectious triggers, and secondary autoimmunity can
be triggered via molecular mimicry or pathogen-induced inflam-
matory environment (125). Indeed, altering the inflammatory
status of DCs alters T cell responses and autoimmune pathol-
ogy [reviewed in Ref. (126)]. Increased inflammation observed
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during autoimmune pathogenesis has several similarities to the
host response to infection, and emerging studies have demon-
strated that DC subsets play distinct roles during infection as well
as during autoimmunity. We hypothesize that cellular responses
including DC-driven immunity associated with a type 1 IFN
signature may be similar regardless if the context is autoimmunity
or chronic viral infections. The counterregulatory pathways asso-
ciated with chronic stimulation could lead to an impaired ability
of DCs to maintain Treg homeostasis.
It has been shown in the context of infection that different
DC subsets can produce T effector responses through distinct
mechanisms. For example, CD8+ DCs induce Th1 responses via
CD70, while CD11b+ DCs induce Th1 responses in an IL-12-
dependent fashion (127). DC subsets can also induce disparate
T cell responses during the same infection. In the lung during
influenza infection, CD103+ DCs induce effector CD8+ T cells
via CD24, while CD11b+ DCs have reduced levels of CD24 and
induce memory CD8+ T cells (128). Targeting of antigen to DC
subsets can strong immunity in a variety of inflammatory settings.
Targeting to cDC1 has long-lasting effects onT cell help for B cells,
increasing responses against microbial pathogens, although this
effect has not been tested for autoantigenic determinants (129).
Targeting of antigen to DCs has also been harnessed in mouse
models in anti-cancer therapeutics that demonstrate the power of
DCs to turn T cell responses against self-tissues to good use. Pro-
tective immune responses against both HER2/neu breast cancer
(cDC1) and melanoma (cDC1 and cDC2) have been induced by
DC-targeted therapies (130, 131).
The type 1 interferons that generate a genetic signature often
observed during autoimmune pathogenesis prior to overt disease
are produced via distinct mechanisms in DC subsets. In response
to measles virus, pDCs produce type 1 interferons through TLR7
or TLR9-MyD88-dependent pathway, while CD8+ DCs can pro-
duce type 1 interferons through Rig-I and MDA5 or TLR3–TRIF
(132). DCs responding to respiratory syncytial virus also produce
distinct T cell profiles. While infected human BDCA-1+ DCs
induce a Th1 response in T cells, BDCA-3+ DCs induce Th2
and Treg responses (133). These distinct responses to pathogens
based on the DC subset responding appear similar to what we
have observed in NOD mice, wherein cDC1 produce effector
responses while cDC2 are tolerogenic. Therefore, the inflamma-
tory environment that is present during autoimmunity or infec-
tion may influence the phenotype of different DC subsets in
distinct manners, and thus produce surprisingly different T cell
responses.
Blocking DC Alterations to Maintain T Cell
Tolerance
Several costimulatory pathways in DCs have been manipulated
to alter disease by affecting activation and proliferation of both
effector T cells and regulatory T cells [reviewed in Ref. (134)].
The NOD mouse has been utilized to study several different
mechanisms of blocking costimulatory pathways, both genetically
and pharmacologically (120, 135, 136). Some of these therapies
have been translated for use in type 1 diabetes patients: treatment
with CTLA-4-Ig was successful in delaying disease, but was not
successful in reversing disease course, with continued loss of
C-peptide, a byproduct of insulin processing that is a marker of
endogenous insulin production (137, 138). In mice, the TNF-
family receptors OX40 and OX40L can be manipulated to prevent
diabetes, probably via changes in regulatory T cells (139, 140).
Although promising results with blockade of CD28 and CD40 in
mousemodels of SLE ameliorate disease and reduce the severity of
disease indicators such as class-switched B cells and autoreactive-
IgG, little efficacy was observed when targeting CD28, CD40,
and ICOS in SLE patients (141–143). Blocking inflammatory
cytokines that can alter DC phenotype has also been examined.
One case report and one small study suggest that TNF-α blockade
in patients with recent onset T1D may preserve beta cell function
(144, 145). The timing of immunotherapies is often critical for
successfully treating autoimmune disease. Several therapies were
successful in reversing diabetes in NOD mice only when used
during specific time intervals, whether those were several weeks
prior to or post disease diagnosis (146).
Implications for Designing New Therapies
to Treat Autoimmunity
Given the relative lack of success at treating autoimmune disease
with therapies targeting a single disease mechanism, it seems that
combination therapies including both an antigen-specific com-
ponent and an alteration of the inflammatory environment will
likely be necessary to ameliorate disease. The central role of DCs
in connecting innate and adaptive immune responsesmakes them
an attractive target for at least part of that therapeutic regimen.
Therefore, incorporation of the knowledge of the developmental
and inflammatory signals that affect DC phenotype is critical
in producing desired therapeutic outcomes. Understanding the
differences in responses of specific DC subsets to these internal
and external influences in the context of specific autoimmune
diseases could lead to a significant increase in the effectiveness
of therapeutics. Therapies designed to target antigen to specific
DC subsets able to induce tolerance in that specific context may
be more successful than non-specific delivery of antigen to many
different APCs with varying activation states and phenotypes.
Likewise, better characterization of the status of costimulatory
molecules on the surface of DC subsets will help to determine
which DC subsets will optimally induce tolerance. Knowing the
leverage points at which DCs will produce effector responses
or suppress T cell responses (especially for known or suspected
initiating antigens) is an important characteristic of which thera-
peutic strategies can take advantage in ameliorating autoimmune
disease.
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